Reneo Pharmaceuticals, Inc. (RPHM) News
Filter RPHM News Items
RPHM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RPHM News Highlights
- For RPHM, its 30 day story count is now at 4.
- Over the past 7 days, the trend for RPHM's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about RPHM are DEC and RARE.
Latest RPHM News From Around the Web
Below are the latest news stories about RENEO PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RPHM as an investment opportunity.
These Stocks under $10 Are Poised To ExplodeIn this piece, we will take a look at these stocks under $10 are poised to explode. If you want to skip our introduction to these tricky stocks, jump to These 5 Stocks Under $10 Are Poised To Explode. The US equity markets remain on track for a strong finish in 2023 as major indices […] |
Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder StudyReneo (RPHM) loses 83% following the failure of the mid-stage pivotal study of its only pipeline candidate, mavodelpar, to treat primary mitochondrial myopathies in adults. It cuts the workforce by 70%. |
Why Is Genetic Disease Focused Reneo Pharmaceuticals Stock Plummeting Today?Reneo Pharmaceuticals Inc (NASDAQ: RPHM) shares are sinking after the company released data from its pivotal STRIDE Phase 2b study of mavodelpar in adult patients with primary mitochondrial myopathies (PMM), a group of mitochondrial diseases that cause prominent muscular problems. The study did not meet its primary efficacy or secondary efficacy endpoint. The trial's primary efficacy endpoint was the change from baseline in the distance walked during the 12-minute walk test (12MWT) at week 24. T |
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced its pivotal STRIDE study (NCT04535609) of mavodelpar in adult patients with primary mitochond |
Reneo Pharmaceuticals Inc (RPHM) Reports Q3 2023 Financial ResultsAnticipation Builds for STRIDE Study Results as R&D Expenses Climb |
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial ResultsTopline data results from the pivotal STRIDE study are expected in December 2023IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update. “We are looking forward to sharing topline results of our |
Reneo Pharmaceuticals to Participate in Upcoming Investor ConferencesIRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate in the following investor conferences. Jefferies London Healthcare Conference Date: Tuesday, November 14 – Thursday, November 16, 2023 Location: The Waldorf Hilton, London, UK Piper |
Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific MeetingsIRVINE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced the company will present a poster titled “Selective peroxisome proliferator-activated receptor (PPAR) delta (δ) agonist, mavodelpar, improves cellular bioenergetics in fibroblasts from patients with mitochondrial complex I deficiency |
12 Best Performing Biotech Stocks in 2023In this piece, we will take a look at the 12 best performing biotechnology stocks in 2023. If you want to skip our introduction to the biotechnology industry and some top players, then check out 5 Best Performing Biotech Stocks in 2023. Biotechnology is one of the hottest industries these days and one that has […] |
Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)Topline data results from the STRIDE study are expected in December 2023IRVINE, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, announced last patient last visit (LPLV) in the pivotal STRIDE study of mavodelpar in PMM. Topline data results from the STRIDE study are expected in December 2023. “This marks |